Table 4.
Groups | A | B | C *+ | D * | E | F | G | H | I |
---|---|---|---|---|---|---|---|---|---|
ΔBW(g) | 28.3 ± 1.6 | -34 ± 5.0 | 11.5 ± 2.4*+ | 3.5 ± 2.7 | 4.2 ± 2.8 | -20 ± 3.2 | -5 ± 5.1 | 17.8 ± 1.7 | 9 ± 6.9 |
Cw /Bw (mg/g) | 2.5 ± 0.7 | 12.9 ± 0.7 | 6.6 ± 0.9*+ | 9.1 ± 0.2 | 8.4 ± 0.2 | 10.7 ± 0.9 | 5.5 ± 0.3* | 4.7 ± 0.4* | 3.6 ± 0.6* |
Ulcerative area (%) | 0.0 ± 0.0 | 69.7 ± 5.3 | 28.6 ± 3.5*+ | 50.2 ± 4.1 | 51.8 ± 3.7 | 71.8 ± 3.9 | 40 ± 7.8* | 24 ± 6.5* | 13.1 ± 0.9* |
Macroscopic score | 0.0 ± 0.0 | 3.0 ± 0.0 | 2.4 ± 0.3 | 2.7 ± 0.2 | 2.7 ± 0.3 | 2.8 ± 0.4 | 2.7 ± 0.2 | 2.1 ± 0.4 | 2.0 ± 0.08 |
ΔBW = Body Weight change; Cw/Bw = Colon weight to body weight ratio; Ulcerative area (%) = Ulceration area /Total area of 8 cm colon; A = Normal group; B = Colitis group; C = Budesonide pectin-coated pellets (300 μg/Kg/day); D = Budesonide solution (300 μg/Kg/day); E = Budesonide uncoated pellets (300 μg/Kg/day); F = Placebo pellets; G = Mesalazine enema (400 mg/Kg/day, rectally); H = Budesonide enema (20 mcg/Kg/day, rectally); I = Prednisolone (5 mg/Kg/day, oral).
The results were expressed as mean ± SEM, (n = 6).*p < 0.05, denote significant difference vs. colitis control group; +p < 0.05 denote significant difference vs. budesonide solution, budesonide uncoated pellets.